Rare, indolent, or incompletely studied: See Endocrine Society guideline B1. These preliminary findings need to be validated by well-designed studies. It is important for clinicians to establish a safe and welcoming environment for transgender patients, with an emphasis on establishing and maintaining rapport Table 1. Active hormone-sensitive malignancy is an absolute contraindication to gender-affirming hormone treatment. Psychosexual outcome of gender-dysphoric children. Adopt and disseminate a nondiscrimination policy.
Breast and reproductive cancers in the transgender population:
Adolescent and Transition Medicine
Excision, excessive skin and subcutaneous tissue includes lipectomy ; abdomen, infraumbilical panniculectomy. Avoid ethinyl estradiol because of unacceptable thromboembolic disease risk. Internalized sense of self as being male, female, or elsewhere along or outside the gender continuum; some persons have complex identities and may identify as agender, gender nonbinary, genderqueer, or gender fluid. Active hormone-sensitive malignancy is an absolute contraindication to gender-affirming hormone treatment. Costa R, Colizzi M. Breakthrough bleeding, decreased bone mineral density, weight gain if overweight or obese.
Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. General term used to describe persons whose gender identity or expression differs from their sex assigned at birth A transgender person designated as male at birth A transgender person designated as female at birth. Coding disease and death. Ask staff to perform a personal assessment of internal biases. Eur Child Adolesc Psychiatry. In the United States, approximatelyyouth and 1. Choose a single article, issue, or full-access subscription.